RiboTargets closes $47mm private round
RiboTargets (anti-infectives and oncology drugs) completed a third round private placement, selling $47mm (UK32mm) of its equity to lead participant JP Morgan and OrbiMed Advisors (both new investors) and returning investors Apax Partners, 3i PLC, Advent Venture Partners, NIB Capital, and Quester.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.